{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:01:07Z","timestamp":1793289667720,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>This study aimed to investigate the feasibility and accuracy of non-radioactive TLN biopsy and TAD in routine clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Background Data:<\/jats:title>\n            <jats:p>TAD involves TLN biopsy (TLNB) and sentinel lymph node biopsy and was recently introduced as a new standard for less invasive axillary staging in BC patients undergoing neoadjuvant systemic therapy (NST); however, clinical evidence is limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The SenTa study is a prospective registry study conducted at 50 centers. Patients with invasive BC who nderwent clip insertion into the most suspicious axillary lymph node were eligible. Axillary surgery was performed with or without sentinel lymph node biopsy, TLNB, and\/or axillary lymph node dissection (ALND). Main endpoints were the detection rate and FNR of TLNB and TAD after NST.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Between 2017 and 2018, 548 consecutive BC patients underwent clip placement into biopsy-confirmed positive lymph nodes. After NST (n = 473), the clipped TLN was intraoperatively resected in 329 of 423 patients [77.8%, 95% confidence interval (CI): 74.0\u201382.0]. TAD was successful in 199 of 229 patients (detection rate: 86.9%, 95% CI: 81.8\u201391.0), the SLN and TLN were identical in 129 patient (64.8%). FNRs were 7.2% (8 of 111, 95% CI: 3.1\u201313.6) for TLNB followed by ALND (n = 203) and 4.3% (2 of 46, 95% CI: 0.5\u201314.8) for TAD followed by ALND (n = 77).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The SenTa study demonstrates the feasibility of TAD in a real-world cohort of BC patients. Our findings are of great importance for de-escalation of surgical strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/sla.0000000000004572","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T10:02:28Z","timestamp":1604656948000},"page":"e553-e562","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":161,"title":["A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients"],"prefix":"10.1097","volume":"276","author":[{"given":"Sherko","family":"Kuemmel","sequence":"first","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany"},{"name":"Klinik f\u00fcrGyn\u00e4kologie mit Brustzentrum Charite\u00b4-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Heil","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rueland","sequence":"additional","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Seiberling","sequence":"additional","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakima","family":"Harrach","sequence":"additional","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Schindowski","sequence":"additional","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Lubitz","sequence":"additional","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hellerhoff","sequence":"additional","affiliation":[{"name":"Breast Unit, Rotkreuzklinikum M\u00fcnchen gGmbH, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ankel","sequence":"additional","affiliation":[{"name":"Breast Unit, Rotkreuzklinikum M\u00fcnchen gGmbH, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Thomas","family":"Gra\u00dfhoff","sequence":"additional","affiliation":[{"name":"Breast Unit, Harzklinikum Dorothea Christiane Erxleben, Wernigerode, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Deuschle","sequence":"additional","affiliation":[{"name":"Breast Unit, Marienhaus Klinikum Hetzelstift Neustadt\/Weinstra\u00dfe, Neustadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Hanf","sequence":"additional","affiliation":[{"name":"Breast Unit Klinikum F\u00fcrth, Frauenklinik Nathanstift, F\u00fcrth, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Belke","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcrGyn\u00e4kologie und Geburtshilfe, Robert-Koch-Krankenhaus Apolda, Apolda, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dall","sequence":"additional","affiliation":[{"name":"Brustzentrum und Gyn\u00e4kologisches Krebszentrum, St\u00e4dtisches Klinikum L\u00fcneburg gGmbH, L\u00fcneburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dorn","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fc r Frauenheilkunde rechts der Isar, TU M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Kaltenecker","sequence":"additional","affiliation":[{"name":"Frauenklinik, St\u00e4dtisches Klinikum KarlsruhegGmbH, Karlsruhe, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Kuehn","sequence":"additional","affiliation":[{"name":"Breast Unit, Klinikum Esslingen, Esslingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Beckmann","sequence":"additional","affiliation":[{"name":"Brustzentrum der Niels-Stensen-Kliniken, Franziskus-Hospital Harderberg, Georgsmarienh\u00fctte, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem","family":"Potenberg","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcrInnere Medizin\/Onkologisches Zentrum, Evangelisches Waldkrankenhaus Spandau, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[{"name":"Breast Center of the Charite\u00b4, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Kostara","sequence":"additional","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Breit","sequence":"additional","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Holtschmidt","sequence":"additional","affiliation":[{"name":"Breast Center, St. Elisabeth-Krankenhaus K\u00f6ln-Hohenlind, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Traut","sequence":"additional","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattea","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"R1-20250424","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-016-4016-4","article-title":"Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade","volume":"160","author":"Hennigs","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"R2-20250424","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/cncr.25152","article-title":"Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer","volume":"116","author":"Dominici","year":"2010","journal-title":"Cancer"},{"key":"R3-20250424","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1634\/theoncologist.2018-0228","article-title":"Neoadjuvant management of early breast cancer: a clinical and investigational position statement","volume":"24","author":"Colomer","year":"2019","journal-title":"Oncologist"},{"key":"R4-20250424","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer","volume":"16","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"key":"R5-20250424","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"R6-20250424","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeo BC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"R7-20250424","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1245\/s10434-018-6531-5","article-title":"Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes","volume":"25","author":"Murphy","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R8-20250424","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4048\/jbc.2017.20.2.119","article-title":"Recent advances in the neoadjuvant treatment of breast cancer","volume":"20","author":"Rubovszky","year":"2017","journal-title":"J Breast Cancer"},{"key":"R9-20250424","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"key":"R10-20250424","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","article-title":"Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy","volume":"153","author":"Barron","year":"2018","journal-title":"JAMA Surg"},{"key":"R11-20250424","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","article-title":"Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery","volume":"152","author":"Tadros","year":"2017","journal-title":"JAMA Surg"},{"key":"R12-20250424","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"R13-20250424","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000492437","article-title":"Current status and future perspectives of axillary management in the neoadjuvant setting","volume":"13","author":"K\u03cbhn","year":"2018","journal-title":"Breast Care"},{"key":"R14-20250424","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"key":"R15-20250424","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1245\/s10434-018-6404-y","article-title":"Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET\/CT and the MARI procedure","volume":"25","author":"van der Noordaa","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R16-20250424","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"key":"R17-20250424","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/SLA.0000000000003075","article-title":"Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer","volume":"269","author":"Simons","year":"2019","journal-title":"Ann Surg"},{"key":"R18-20250424","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"key":"R19-20250424","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","article-title":"Axillary nodal management following neoadjuvant chemotherapy: a review","volume":"3","author":"Pilewskie","year":"2017","journal-title":"JAMA Oncol"},{"key":"R20-20250424","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000501000","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2019","volume":"14","author":"Ditsch","year":"2019","journal-title":"Breast Care"},{"key":"R22-20250424","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s00268-017-4171-8","article-title":"Feasibility of preoperative axillary lymph node marking with a clip in breast cancer patients before neoadjuvant chemotherapy: a preliminary study","volume":"42","author":"Kim","year":"2018","journal-title":"World J Surg"},{"key":"R23-20250424","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.suronc.2019.05.019","article-title":"Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: preliminary results","volume":"30","author":"Flores-Funes","year":"2019","journal-title":"Surg Oncol"},{"key":"R24-20250424","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1245\/s10434-018-6548-9","article-title":"Intraoperative touch imprint cytology in targeted axillary dissection after neoadjuvant chemotherapy for breast cancer patients with initial axillary metastasis","volume":"25","author":"Wu","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R25-20250424","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1245\/s10434-017-6270-z","article-title":"Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA Trial)","volume":"25","author":"Siso","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R26-20250424","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","article-title":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial","volume":"19","author":"Henke","year":"2018","journal-title":"Trials"},{"key":"R27-20250424","doi-asserted-by":"crossref","first-page":"641","DOI":"10.6004\/jnccn.2016.0181","article-title":"NCCN guidelines update: breast cancer","volume":"14","author":"Gradishar","year":"2016","journal-title":"J Natl Compr Cancer Netw"},{"key":"R28-20250424","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.6004\/jnccn.2018.0083","article-title":"Breast cancer screening and diagnosis, version 3.2018","volume":"16","author":"Jacobs","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"key":"R30-20250424","first-page":"297","article-title":"Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome","volume":"180","author":"Sataloff","year":"1995","journal-title":"J Am Coll Surg"},{"key":"R31-20250424","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1055\/a-0646-4630","article-title":"Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-level, AWMF registry number 032\/0450L, December 2017) - part 2 with recommendations for the therapy of primary, recurrent and advanced Br","volume":"78","author":"W\u00f6ckel","year":"2018","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"R32-20250424","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/bjs.10626","article-title":"Targeted axillary dissection after neoadjuvant therapy in breast cancer","volume":"105","author":"Ahmed","year":"2018","journal-title":"Br J Surg"},{"key":"R33-20250424","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/bjs.11320","article-title":"Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer","volume":"106","author":"Simons","year":"2019","journal-title":"Br J Surg"},{"key":"R34-20250424","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1200\/JCO.18.02092","article-title":"Prospective, multicenter, randomized phase III trial evaluating the impact of lymphoscintigraphy as part of sentinel node biopsy in early breast cancer: Senszi (GBG80) trial","volume":"37","author":"Kuemmel","year":"2019","journal-title":"J Clin Oncol"},{"key":"R35-20250424","first-page":"2705","article-title":"Reply to","volume":"37","author":"Holtschmidt","year":"2019","journal-title":"to E. Hindi\u00e9 and A.K. Goel et al. J Clin Oncol"}],"container-title":["Annals of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SLA.0000000000004572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T01:13:09Z","timestamp":1745457189000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SLA.0000000000004572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/sla.0000000000004572","relation":{},"ISSN":["0003-4932"],"issn-type":[{"value":"0003-4932","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,4]]}}}